FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2078941339> ?p ?o ?g. }

• W2078941339 endingPage "2039" @default.
• W2078941339 startingPage "2038" @default.
• W2078941339 abstract "It was estimated that over 44,000 people would be diagnosed with thyroid cancer in the United States in 2010 (1). With appropriate initial treatment, the majority of those patients can expect to achieve good disease-specific outcomes. However, up to 30% of patients (2) will suffer persistent disease or recurrences, the majority of which are fortunately localized to cervical lymph nodes. Although recommendations for the initial management of well-differentiated thyroid cancer are well-formulated and have considerable evidence behind them, gathered over many decades of careful follow-up, recommendations for therapeutic options for recurrent or persistent disease have less clarity. Historically, this has been a difficult literature. There have been variations in surgical technique and shifts in the use of adjuvant radioactive iodine therapy. There have been improvements in thyroglobulin assays over time and thus, changing definitions of biochemical cure. We have shifted paradigms for disease detection modalities, performing more frequent TSH-stimulated thyroglobulin assessments since the Food and Drug Administration approval of recombinant human TSH and have dramatically increased the utilization of high-resolution neck ultrasonography. In older studies, the criteria for cure after surgery was often not rigorous, or detailed information on disease assessment postoperatively was not provided. Furthermore, direct comparison of different modalities of therapy and combinations of therapy (e.g. radioactive iodine and/or surgical resection) have been rare, and those studies, such as Coburn et al. (3), usually were not randomized and suffered from significant selection bias. The 2009 Revised American Thyroid Association Management Guidelines for Patients with Thyroid Nodules and Differentiated Thyroid Cancer recommend surgical management of locoregional disease in the absence of distant metastases with an evidence rating of B (based on fair evidence that the service or intervention can improve important health outcomes) (4). Literature subsequent to that reviewed for the 2009 Revised Guidelines, including the paper by Yim et al. (5) published in this issue of the JCEM, contribute additional information to be considered in the assessment of the efficacy of lymph node dissection for locoregional disease. Specifically, three recent studies suggest that surgical intervention for locoregional recurrence can indeed achieve biochemical remission (undetectable TSH-stimulated serum thyroglobulin).LymphnodedissectionachievesaTSH-stimulatedthyroglobulinof less than1.0ng/ml in29%ofpatients (6) and less than 2.0 ng/ml in 41–46% of patients in one to three lymph node dissections (6, 7). Clayman et al. (8) reported obtaining an undetectable thyroglobulin ( 3 ng/ml) in 71% of informative cases. The paper by Yim et al. (5) describes a careful analysis of a relatively large series of 83 patients who underwent surgical intervention for recurrent/persistent papillary thyroid carcinoma. The authors report achieving a biochemical remission (undetectable TSH-stimulated thyroglobulin less than 1.0 ng/ml) in 51% of patients and less than 2.0 ng/ml in 61% of patients. Additional important findings in this study were that higher preoperative thyroglobulin levelspredicted failure toachieveabiochemical and clinical remission. However, there was only a tendency toward the number of pathological nodes to predict biochemical remission and no impact of the number of removed nodes, number of malignant nodes, extent of reoperation or adjunctive radioactive iodine on achieving" @default.
• W2078941339 created "2016-06-24" @default.
• W2078941339 creator A5068216862 @default.
• W2078941339 date "2011-07-01" @default.
• W2078941339 modified "2023-10-12" @default.
• W2078941339 title "Management of Recurrent/Persistent Papillary Thyroid Carcinoma: Efficacy of the Surgical Option" @default.
• W2078941339 cites W1510228191 @default.
• W2078941339 cites W1964921094 @default.
• W2078941339 cites W1991674686 @default.
• W2078941339 cites W2033297297 @default.
• W2078941339 cites W2057896103 @default.
• W2078941339 cites W2059323295 @default.
• W2078941339 cites W2088828338 @default.
• W2078941339 cites W2089575163 @default.
• W2078941339 cites W2116542352 @default.
• W2078941339 cites W2142143758 @default.
• W2078941339 cites W2155082105 @default.
• W2078941339 cites W2167719032 @default.
• W2078941339 cites W2186996327 @default.
• W2078941339 doi "https://doi.org/10.1210/jc.2011-1663" @default.
• W2078941339 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21734006" @default.
• W2078941339 hasPublicationYear "2011" @default.
• W2078941339 type Work @default.
• W2078941339 sameAs 2078941339 @default.
• W2078941339 citedByCount "24" @default.
• W2078941339 countsByYear W20789413392012 @default.
• W2078941339 countsByYear W20789413392013 @default.
• W2078941339 countsByYear W20789413392014 @default.
• W2078941339 countsByYear W20789413392016 @default.
• W2078941339 countsByYear W20789413392019 @default.
• W2078941339 countsByYear W20789413392020 @default.
• W2078941339 countsByYear W20789413392021 @default.
• W2078941339 countsByYear W20789413392022 @default.
• W2078941339 countsByYear W20789413392023 @default.
• W2078941339 crossrefType "journal-article" @default.
• W2078941339 hasAuthorship W2078941339A5068216862 @default.
• W2078941339 hasBestOaLocation W20789413391 @default.
• W2078941339 hasConcept C126322002 @default.
• W2078941339 hasConcept C134018914 @default.
• W2078941339 hasConcept C143998085 @default.
• W2078941339 hasConcept C2777546739 @default.
• W2078941339 hasConcept C2993294228 @default.
• W2078941339 hasConcept C526584372 @default.
• W2078941339 hasConcept C61434518 @default.
• W2078941339 hasConcept C71924100 @default.
• W2078941339 hasConceptScore W2078941339C126322002 @default.
• W2078941339 hasConceptScore W2078941339C134018914 @default.
• W2078941339 hasConceptScore W2078941339C143998085 @default.
• W2078941339 hasConceptScore W2078941339C2777546739 @default.
• W2078941339 hasConceptScore W2078941339C2993294228 @default.
• W2078941339 hasConceptScore W2078941339C526584372 @default.
• W2078941339 hasConceptScore W2078941339C61434518 @default.
• W2078941339 hasConceptScore W2078941339C71924100 @default.
• W2078941339 hasIssue "7" @default.
• W2078941339 hasLocation W20789413391 @default.
• W2078941339 hasLocation W20789413392 @default.
• W2078941339 hasOpenAccess W2078941339 @default.
• W2078941339 hasPrimaryLocation W20789413391 @default.
• W2078941339 hasRelatedWork W1981968121 @default.
• W2078941339 hasRelatedWork W2011960454 @default.
• W2078941339 hasRelatedWork W2021841321 @default.
• W2078941339 hasRelatedWork W2060603500 @default.
• W2078941339 hasRelatedWork W2070295037 @default.
• W2078941339 hasRelatedWork W2088569338 @default.
• W2078941339 hasRelatedWork W2155312245 @default.
• W2078941339 hasRelatedWork W2163236351 @default.
• W2078941339 hasRelatedWork W2411536504 @default.
• W2078941339 hasRelatedWork W2748952813 @default.
• W2078941339 hasVolume "96" @default.
• W2078941339 isParatext "false" @default.
• W2078941339 isRetracted "false" @default.
• W2078941339 magId "2078941339" @default.
• W2078941339 workType "article" @default.